Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab + axitinib for recurrent glioblastoma (Phase II)
2017-000200-23Phase 2Completed
- Sponsor
- UZ Brussel
- Start
- Apr 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of avelumab and axitinib in glioblastoma (GBM), sponsored by UZ Brussel. Primary endpoint: 6-month progression-free survival. Started Apr 2017; status: completed.
02
Drugs
avelumabaxitinib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2017-000200-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000200-23.